DataSheet1_Induction of Mitosis Delay and Apoptosis by CDDO-TFEA in Glioblastoma Multiforme.ZIP
Background: Glioblastoma multiforme (GBM) is the vicious malignant brain tumor in adults. Despite advances multi-disciplinary treatment, GBM constinues to have a poor overall survival. CDDO-trifluoroethyl-amide (CDDO-TEFA), a trifluoroethylamidederivative of CDDO, is an Nrf2/ARE pathway activator. CDDO-TEFEA is used to inhibit proliferation and induce apoptosis in glioma cells. However, it not clear what effect it may have on tumorigenesis in GBM.
Methods: This in vitro study evaluated the effects of CDDO-TFEA on GBM cells. To do this, we treated GBM8401 cell lines with CDDO-TFEA and assessed apoptosis, cell cycle. DNA content and induction of apoptosis were analyzed by flow cytometry and protein expression by Western blot analysis.
Results: CDDO-TFEA significantly inhibited the cell viability and induced cell apoptosis on GBM 8401 cell line. The annexin-FITC/PI assay revealed significant changes in the percentage of apoptotic cells. Treatment with CDDO-TFEA led to a significant reduction in the GBM8401 cells’ mitochondrial membrane potential. A significant rise in the percentage of caspase-3 activity was detected in the treated cells. In addition, treatment with CDDO-TFEA led to an accumulation of G2/M-phase cells. In addition, these results suggest that regarding increased protein synthesis during mitosis in the MPM-2 staining, indicative of a delay in the G2 checkpoint. An analysis of Cyclin B1, CDK1, Cyclin B1/CDK1 complex and CHK1 and CHK2 expression suggested that cell cycle progression seems also to be regulated by CDDO-TFEA. Therefore, CDDO-TFEA may not only induce cell cycle G2/M arrest, it may also exert apoptosis in established GBM cells.
Conclusion: CDDO-TFEA can inhibit proliferation, cell cycle progression and induce apoptosis in GBM cells in vitro, possibly though its inhibition of Cyclin B1, CDK1 expression, and Cyclin B1/CDK1 association and the promotion of CHK1 and CHK2 expression.
History
References
- https://doi.org//10.1101/gad.914401
- https://doi.org//10.4161/cbt.7.5.5713
- https://doi.org//10.1186/1471-2407-8-391
- https://doi.org//10.1007/978-1-4939-0888-2_3
- https://doi.org//10.1016/s0092-8674(00)81265-9
- https://doi.org//10.3390/molecules24224097
- https://doi.org//10.1002/ijc.1311
- https://doi.org//10.1007/s10143-016-0709-8
- https://doi.org//10.1055/s-0037-1620238
- https://doi.org//10.1158/0008-5472.CAN-03-3906
- https://doi.org//10.1111/jcmm.14250
- https://doi.org//10.1083/jcb.153.1.121
- https://doi.org//10.1006/excr.2000.4889
- https://doi.org//10.1002/jcb.28202
- https://doi.org//10.1083/jcb.153.1.137
- https://doi.org//10.1158/0008-5472.CAN-13-3440
- https://doi.org//10.1038/cdd.2011.154
- https://doi.org//10.1016/j.cell.2011.02.013
- https://doi.org//10.1126/science.2683079
- https://doi.org//10.1182/blood.v98.9.2603
- https://doi.org//10.1155/2012/396573
- https://doi.org//10.1021/jf1016303
- https://doi.org//10.1124/mol.59.5.1094
- https://doi.org//10.5483/bmbrep.2008.41.1.011
- https://doi.org//10.1083/jcb.141.4.875
- https://doi.org//10.1126/science.aaf7463
- https://doi.org//10.1038/35043058
- https://doi.org//10.1126/science.275.5303.1132
- https://doi.org//10.1002/j.1460-2075.1991.tb04897.x
- https://doi.org//10.1016/s0092-8674(00)80434-1
- https://doi.org//10.1158/1078-0432.CCR-16-0083
- https://doi.org//10.1016/s0092-8674(00)80085-9
- https://doi.org//10.1038/nrc2602
- https://doi.org//10.1016/j.freeradbiomed.2011.03.027
- https://doi.org//10.1038/344503a0
- https://doi.org//10.1038/srep00201
- https://doi.org//10.1182/blood-2002-04-1174
- https://doi.org//10.1038/sj.bjc.6602735
- https://doi.org//10.2174/1871520618666180105161136
- https://doi.org//10.1016/j.canlet.2014.01.016
- https://doi.org//10.1038/nrm3546
- https://doi.org//10.1017/erm.2020.3
- https://doi.org//10.1016/j.freeradbiomed.2010.03.017
- https://doi.org//10.1074/jbc.M108974200
- https://doi.org//10.1007/s00384-008-0551-8
- https://doi.org//10.1074/jbc.273.42.27084
- https://doi.org//10.1111/j.1349-7006.2007.00444.x
- https://doi.org//10.1016/s0955-0674(00)00149-6
- https://doi.org//10.1155/2021/5552226
- https://doi.org//10.1007/BF01269891
- https://doi.org//10.2147/DDDT.S68872
- https://doi.org//10.2147/DDDT.S80958
- https://doi.org//10.1186/1476-4598-13-30
- https://doi.org//10.1016/j.devcel.2014.03.012
- https://doi.org//10.1007/s00018-002-8510-y
- https://doi.org//10.1016/j.expneurol.2019.113142
- https://doi.org//10.1038/sj.onc.1207757
- https://doi.org//10.1093/neuonc/noy074
- https://doi.org//10.1038/35044005